MonTa shares publication of MBS8 and how our TLR7 agonist demonstrates superior anti tumor activity in preclinical studies.
Some of the groundbreaking preclinical research that laid the foundation for starting MonTa Biosciences has just been published — and it’s worth celebrating.
This publication highlights the exceptional immune activation and tumor response we observed in mouse models using our TLR7 agonist, MBS8, formulated in lipid micelles.
Not only did we see superior efficacy compared to benchmark compounds like Resiquimod, but we also uncovered key insights into the mechanism of action that explain this amazing anti-tumor activity with significant tumor suppression in all models tested. We also show education of the immune system to recognize and kill tumor cells without further treatment – simply by empowering the strength and adaptability of the immune system to fight cancer. This was the spark that led us to found MonTa Biosciences years back.
We’re thrilled to continue pushing the boundaries of cancer immunotherapy and look forward to treat patients to unravel the full potential of MBS8.
Thanks to our co-authors, employees, investors, clinical sites and patients for making this possible.
Find the publication here: https://lnkd.in/de_DKk6X